Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

5(62.5%)

Phase 3

2(25.0%)

Phase 1

1(12.5%)

8Total

N/A(5)

Phase 3(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT03963596Not ApplicableCompleted

Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Myopia

Role: collaborator

NCT04292756Not ApplicableCompleted

Triamcinolone Acetonide in Patients With Serous Pigment Epithelial Detachment

Role: collaborator

NCT04976244Not ApplicableUnknown

Brolucizumab for CNV Associated With Pathologic Myopia

Role: collaborator

NCT04245072Not ApplicableUnknown

Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Central Chorioretinitis

Role: collaborator

NCT04119219Not ApplicableUnknown

Antiangiogenic Therapy of CNV Associated With Angioid Streaks

Role: collaborator

NCT01780285Phase 3Unknown

Laparoscopic Repair of Giant Hiatal Hernias With Nitinol-framed Lightweight Polytetrafluoroethylene Mesh

Role: lead

NCT01408108Phase 3Unknown

Laparoscopic Lightweight Mesh Repair of Large Hiatal Hernias

Role: lead

NCT01540162Completed

Experience of Mutaflor Suspension Use in Preterm Infants for Immunity Improvement

Role: lead

NCT01615250Phase 1Unknown

Implantation of Peripheral Stem Cells in Patient With Ischemic Cardiomyopathy

Role: lead

All 9 trials loaded